This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
B cell lymphoma	Unknown	<p>Mouse studies suggest <i>Lactobacillus johnsonii</i> supplementation could help prevent ataxia-telangiectasia-associated B cell lymphomas. In a mouse model of ataxia telangiectasia, mice from a colony with late lymphoma onset and longer lifespans had higher amounts of <i>L. johnsonii</i> in the gut than did mice from a colony with early lymphoma onset and shorter lifespans. In mice with earlier lymphoma onset, oral administration of <i>L. johnsonii</i> decreased markers of lymphoma risk such as systemic micronucleus formation, inflammation and DNA damage compared with saline administration. Next steps include identifying additional bacterial strains that could be used to reduce lymphoma incidence and progression in the mouse model.</p> <p>Corresponding author Robert Schiestl has founded Microbio Pharma Inc. to commercialize the findings.</p> <p>SciBX 6(31); doi:10.1038/scibx.2013.818 Published online Aug. 15, 2013</p>	Covered by two pending patents; licensing details available from corresponding authors	<p>Yamamoto, M.L. <i>et al. Cancer Res.</i>; published online July 15, 2013; doi:10.1158/0008-5472.CAN-13-0022 Contact: Robert H. Schiestl, University of California, Los Angeles, Calif. e-mail: rschiestl@mednet.ucla.edu Contact: James Borneman, University of California, Riverside, Calif. e-mail: borneman@ucr.edu</p>